Biphenyl

Biphenyl

SCHEMBL5748779

CC(=O)ON.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 3/20 0.54
BACE1 P56817 1/20 0.46
ALDH1A1 P00352 3/20 0.45
SRR Q9GZT4 2/20 0.44
PSAT1 Q9Y617 2/20 0.44
CYP1A2 P05177 1/20 0.44
GAA P10253 1/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
PTGS2 P35354 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
ELANE P08246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6223235 0.83 ALDH1A1 (0.43) SMN1; SMN2MAPTBACE1ALDH1A1CYP1A2
Aniline SCHEMBL15936366 0.83 TSHR (0.52) MAPTALDH1A1GAACYP2C19PTGS2
Biphenyl SCHEMBL27819830 0.82 SMN1; SMN2 (0.56) SMN1; SMN2MAPTBACE1ALDH1A1CYP2C19
Biphenyl SCHEMBL6269566 0.82 MAPT (0.56) SMN1; SMN2MAPTBACE1ALDH1A1CYP1A2
Biphenyl SCHEMBL8773175 0.82 SMN1; SMN2 (0.56) SMN1; SMN2MAPTBACE1ALDH1A1CYP1A2
Biphenyl SCHEMBL2670012 0.81 MAPT (0.61) SMN1; SMN2MAPTALDH1A1GAACYP2C19
Biphenyl SCHEMBL27766330 0.81 SMN1; SMN2 (0.61) SMN1; SMN2MAPTALDH1A1GAAPTGS2
Biphenyl SCHEMBL1822628 0.81 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9
Benzene SCHEMBL4654902 0.81 FFAR3 (0.47) MAPTALDH1A1GAAPTGS2TDP1
Biphenyl SCHEMBL29059196 0.81 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1GAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109568300-A Felbinac or its salt are preparing the application in Xa inhibitor medicaments 石家庄以岭药业股份有限公司 2019-04-05 CN claimed
CN-106983718-B A kind of preparation method of felbinac or its tromethamine saline injection 广东中科药物研究有限公司 2019-01-11 CN claimed
CN-106983718-A A kind of preparation method of felbinac or its tromethamine saline injection 广东中科药物研究有限公司 2017-07-28 CN claimed
CN-105769758-A Felbinac salt eye drops, as well as preparation method and application thereof 广东中科药物研究有限公司 2016-07-20 CN claimed
CN-103169653-A Biphenylacetic acid and novel use of biphenylacetate GUANGDONG ZONK DRUG R & D LTD 2013-06-26 CN claimed
CN-102885803-A Application of felbinac tromethamine salt to preparation of medicine for treating eye inflammatory reactions GUANGDONG ZONK DRUG R & D LTD 2013-01-23 CN claimed
CN-101331112-B Biphenyl acetate as well as preparation method and application thereof GUANGDONG ZONK DRUG R & D LTD 2012-03-21 CN claimed
CN-101168502-B Biphenyl ammonia acetate butantriol salt and preparation method thereof GUANGDONG ZONK DRUG R & D LTD 2010-09-08 CN claimed
CN-101331112-A Biphenyl acetate as well as preparation method and application thereof GUANGDONG ZONK DRUG R & D LTD (CN) 2008-12-24 CN claimed
CN-101168502-A Biphenyl ammonia acetate butantriol salt and preparation method thereof GUANGDONG ZONK DRUG R & D LTD (CN) 2008-04-30 CN claimed
CN-101156841-A An antineoplastic new use of biphenyl acetic acid and its salt WENZHAN CHEN (CN) 2008-04-09 CN claimed
CN-1944378-A Biphenyl ammonia acetate butantriol salt and its preparing method ZHONGKE MEDICINE RES CO LTD GU (CN) 2007-04-11 CN claimed
CN-110290781-A The dosage form of stomach and intestine privileged site control release 南京三迭纪医药科技有限公司 2019-09-27 CN disclosed
CN-107847398-B Control the pharmaceutical dosage form of release 南京三迭纪医药科技有限公司 2019-05-07 CN disclosed
CN-109568300-A Felbinac or its salt are preparing the application in Xa inhibitor medicaments 石家庄以岭药业股份有限公司 2019-04-05 CN disclosed
CN-109432039-A Pharmaceutical formulation and its use 南京三迭纪医药科技有限公司 2019-03-08 CN disclosed
US-20050096335-A1 Heteroaryl - fused nitrogen heterocycles as therapeutic agents TRANSTECH PHARMA, INC. 2005-05-05 US disclosed
EP-1438310-A1 BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS TransTech Pharma Inc. (US) 2004-07-21 EP disclosed
US-20040014778-A1 Heteroaryl - fused nitrogen heterocycles as therapeutic agents VTVX HOLDINGS I LLC 2004-01-22 US disclosed
WO-2003033496-A1 BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS TRANSTECH PHARMA, INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014778-A1 Heteroaryl - fused nitrogen heterocycles as therapeutic agents PTPRG, PTPRM, PTPRC SMN1; SMN2 3945/4885MAPT 770/4885BACE1 261/4885
US-20050096335-A1 Heteroaryl - fused nitrogen heterocycles as therapeutic agents PTPRG, PTPRM, PTPRC SMN1; SMN2 3945/4885MAPT 770/4885BACE1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.